AstraZeneca Stock - Analyst focus and drug pipeline backdrop
21.06.2026 - 14:15:56 | ad-hoc-news.de
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/21/2026, 14:15 CET. Details in the imprint.
AstraZeneca (US6549022043) remains one of the most closely watched global pharma names as investors track its extensive late-stage pipeline and oncology franchise. With no new market-moving company announcement today, the spotlight is on current analyst estimates and positioning around the stock.
All news and analysis on AstraZeneca stock
Key figures, news and background on AstraZeneca stock, including analyst expectations and upcoming milestones, can be found in the dedicated topic area.
What current estimates suggest
Analyst coverage on AstraZeneca remains broad, reflecting its large market capitalization and diversified portfolio across oncology, cardiovascular, renal, metabolism and respiratory diseases. Consensus data compiled on major financial platforms still points to a predominantly positive stance, with a majority of Buy ratings reported for the stock on recent snapshots.
Average twelve-month price targets published across these platforms continue to imply upside from recent trading levels, underlining expectations for sustained earnings growth from key cancer therapies and new launches. Individual targets and ratings vary by house, but the aggregate picture remains constructive according to available consensus overviews.
How analysts frame the story
Sell-side research has in recent months largely centered on AstraZeneca’s oncology franchise, notably drugs such as Tagrisso and Imfinzi, as well as its growing presence in antibody-drug conjugates and other targeted therapies. Analysts also emphasize the company’s sizable late-stage pipeline and its ability to replenish revenue as older products face competition.
On the risk side, reports frequently highlight pricing pressures, patent-expiry dynamics and execution risk around late-stage trials and regulatory decisions. Net-net, coverage tends to describe AstraZeneca as a growth-oriented large-cap pharma with above-sector exposure to oncology and a busy newsflow calendar over the medium term.
What the company sells
AstraZeneca generates most of its revenue from prescription medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases. Flagship oncology products include targeted cancer therapy Tagrisso and immunotherapy Imfinzi, which are approved in multiple major markets and remain central earnings drivers.
Where the stock trades today
AstraZeneca stock (US6549022043) trades in the United States via its New York-listed shares, where the most recently cited price was around $174.93 on 06/21/2026 in US trading, based on publicly available quote data.
Key facts on AstraZeneca stock
- Company: AstraZeneca PLC
- ISIN: US6549022043
- Ticker: AZN
- Venue: Nasdaq (US listing)
- Price (as of 06/21/2026, 14:15 CET): 174.93 USD
- Market cap: data based on latest available public quote
- Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
- Index membership: major international benchmarks via primary London listing
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
